Q-omics provides the consensus-scored RNF227 profile across patient tissues and cancer cell-line models. RNF227 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RNF227 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RNF227 RNA expression shows 19,648 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where RNF227 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF227 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF227 survival associations across molecular data types. RNF227 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF227 RNA expression–survival associations across cancer types. High RNF227 expression shows unfavorable associations in KICH, LIHC and LGG, but favorable associations in UCS, BRCA and CESC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for RNF227 RNA expression.
This table summarizes RNF227 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF227. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF227 shows lower tumor expression in LUAD and UCEC and higher tumor expression in KIRC, COAD, LIHC and BLCA. The KIRC box plot shows higher RNF227 RNA expression in tumor versus normal tissue (log2 FC = +0.557, t-test p < 0.001).
This table shows molecular features associated with RNF227 in patient tissues and cancer cell lines. In patient samples, RNF227 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF227 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
